Several studies have indicated that peripheral adiponectin levels are elevated in patients with chronic schizophrenia, concluding that adiponectin could be a marker for the metabolic syndrome for schizophrenia, especially that triggered by atypical antipsychotics, rather than reflecting the disease (38–42). This evidence concerns the gene ADIPOQ and schizophrenia.